BioTTT001 injection

BIOLOGICAL4 trials

Sponsors

Beijing Bio-Targeting Therapeutics Technology Co., Ltd, Henan Cancer Hospital

Conditions

Locally Advanced Breast Cancer (LABC)Meningeal MetastasisRecurrent High-grade GliomaSolid Tumor

Phase 1

A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors

Enrolling by invitationNCT06215846

Beijing Bio-Targeting Therapeutics Technology Co., LtdSolid Tumor

Start: 2024-05-07End: 2026-06-28Target: 12Updated: 2025-11-26

Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.

Enrolling by invitationNCT06763965

Beijing Bio-Targeting Therapeutics Technology Co., LtdRecurrent High-grade Glioma

Start: 2024-11-26End: 2027-07-31Target: 30Updated: 2026-03-23

A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer

WithdrawnNCT07150767

Beijing Bio-Targeting Therapeutics Technology Co., LtdLocally Advanced Breast Cancer (LABC)

Start: 2025-03-26End: 2027-03-26Updated: 2025-12-02

Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of BioTTT001

RecruitingNCT07264569

Henan Cancer HospitalMeningeal Metastasis

Start: 2025-06-25End: 2027-12-30Target: 42Updated: 2025-12-04